The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SRPT | -82.72% | -83.44% | -30.18% | -42% |
| S&P | +16.9% | +95.99% | +14.39% | +708% |
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $611.09M | 68.4% |
| Gross Profit | $447.69M | 44.6% |
| Gross Margin | 73.26% | -12.1% |
| Market Cap | $1.68B | -88.7% |
| Market Cap / Employee | $1.22M | 0.0% |
| Employees | 1.4K | 4.4% |
| Net Income | $196.89M | 2947.9% |
| EBITDA | $130.44M | 984.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $510.60M | 33.1% |
| Accounts Receivable | $527.30M | 46.5% |
| Inventory | 994 | 104.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.35B | 5.9% |
| Short Term Debt | $0.00M | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -1.63% | -3.1% |
| Return On Invested Capital | -20.55% | 10.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $229.54M | 1713.6% |
| Operating Free Cash Flow | $261.34M | 1649.0% |
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 1946.77 | 390.61 | 103.75 | 51.01 | - |
| Price to Book | 9.77 | 9.51 | 4.05 | 1.47 | -90.53% |
| Price to Sales | 7.65 | 6.93 | 2.78 | 0.73 | -92.60% |
| Price to Tangible Book Value | 9.99 | 9.73 | 4.12 | 1.50 | -90.60% |
| Enterprise Value to EBITDA | 350.82 | 74.87 | -24.56 | 18.22 | -98.52% |
| Return on Equity | 12.3% | 19.7% | -23.6% | -4.8% | -191.53% |
| Total Debt | $1.40B | $1.34B | $1.34B | $1.35B | -1.17% |
Hit-or-miss data, delays, and contentious debate preceded the FDA's green-lighting of the first drug to target the cause of Duchenne muscular dystrophy. Meanwhile, a disappointing data readout stops one vaccine maker in its tracks.
Discussing the details behind the FDA's negative vote on Sarepta's DMD drug and Gilead Sciences' sliding hepatitis C sales.
SRPT earnings call for the period ending December 31, 2024.
SRPT earnings call for the period ending September 30, 2024.
SRPT earnings call for the period ending June 30, 2024.
SRPT earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
